FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1911378052> ?p ?o ?g. }

• W1911378052 endingPage "1194" @default.
• W1911378052 startingPage "1189" @default.
• W1911378052 abstract "Abstract Objectives Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used in ophthalmology (off-label) for the treatment of neovascularization in diseases such as diabetic retinopathy and age-related macular degeneration (wet form). Bevacizumab is currently administrated by repeated intravitreal injection, which can cause severe complications; a non-invasive delivery route is therefore desirable. The passive permeation of bevacizumab through isolated human sclera was evaluated and the iontophoretic technique was explored as a method to enhance its transscleral transport in vitro. Methods Bevacizumab was fluorescently labelled using fluorescein isothiocyanate (FITC). Permeation experiments were conducted for 2 h in Franz-type diffusion cells using human sclera as the barrier. The donor compartment contained FITC-bevacizumab (2.5 mg/ml) in phosphate-buffered saline at pH 7.4. In the iontophoretic experiments, a current intensity of 2.3 mA (current density 3.8 mA/cm2) was applied. The permeation samples were analysed with a fluorescence detector (excitation and emission wavelengths were 490 and 520 nm, respectively). The stability of FITC-bevacizumab conjugate was checked by thin layer chromatography. Key findings The main finding of this work is that anodal iontophoresis can significantly enhance bevacizumab transport through isolated human sclera (enhancement factor 7.5), even though the drug is essentially uncharged. Due to the relatively constant characteristics of antibodies, these results can probably be extended to other molecules of the same family. Conclusions Preliminary results indicate that anodal iontophoresis could be a promising strategy to non-invasively deliver bevacizumab through the sclera. The presence in the eye of other barriers, both static and dynamic, necessitates further evaluation of the technique on more complex ex-vivo and in-vivo models." @default.
• W1911378052 created "2016-06-24" @default.
• W1911378052 creator A5003589003 @default.
• W1911378052 creator A5012650397 @default.
• W1911378052 creator A5027026143 @default.
• W1911378052 creator A5033794388 @default.
• W1911378052 creator A5073074936 @default.
• W1911378052 creator A5076630196 @default.
• W1911378052 date "2010-08-02" @default.
• W1911378052 modified "2023-10-17" @default.
• W1911378052 title "In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application" @default.
• W1911378052 cites W1972187956 @default.
• W1911378052 cites W1974514441 @default.
• W1911378052 cites W2006746185 @default.
• W1911378052 cites W2014262451 @default.
• W1911378052 cites W2015799566 @default.
• W1911378052 cites W2016393330 @default.
• W1911378052 cites W2016936614 @default.
• W1911378052 cites W2018809350 @default.
• W1911378052 cites W2021318919 @default.
• W1911378052 cites W2023903257 @default.
• W1911378052 cites W2035625594 @default.
• W1911378052 cites W2039881653 @default.
• W1911378052 cites W2047592628 @default.
• W1911378052 cites W2048206929 @default.
• W1911378052 cites W2061480740 @default.
• W1911378052 cites W2074208432 @default.
• W1911378052 cites W2084317082 @default.
• W1911378052 cites W2139359833 @default.
• W1911378052 cites W3102433126 @default.
• W1911378052 doi "https://doi.org/10.1111/j.2042-7158.2010.01153.x" @default.
• W1911378052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20796199" @default.
• W1911378052 hasPublicationYear "2010" @default.
• W1911378052 type Work @default.
• W1911378052 sameAs 1911378052 @default.
• W1911378052 citedByCount "42" @default.
• W1911378052 countsByYear W19113780522012 @default.
• W1911378052 countsByYear W19113780522013 @default.
• W1911378052 countsByYear W19113780522014 @default.
• W1911378052 countsByYear W19113780522015 @default.
• W1911378052 countsByYear W19113780522016 @default.
• W1911378052 countsByYear W19113780522017 @default.
• W1911378052 countsByYear W19113780522018 @default.
• W1911378052 countsByYear W19113780522019 @default.
• W1911378052 countsByYear W19113780522020 @default.
• W1911378052 countsByYear W19113780522021 @default.
• W1911378052 countsByYear W19113780522022 @default.
• W1911378052 countsByYear W19113780522023 @default.
• W1911378052 crossrefType "journal-article" @default.
• W1911378052 hasAuthorship W1911378052A5003589003 @default.
• W1911378052 hasAuthorship W1911378052A5012650397 @default.
• W1911378052 hasAuthorship W1911378052A5027026143 @default.
• W1911378052 hasAuthorship W1911378052A5033794388 @default.
• W1911378052 hasAuthorship W1911378052A5073074936 @default.
• W1911378052 hasAuthorship W1911378052A5076630196 @default.
• W1911378052 hasBestOaLocation W19113780521 @default.
• W1911378052 hasConcept C118487528 @default.
• W1911378052 hasConcept C126838900 @default.
• W1911378052 hasConcept C134306372 @default.
• W1911378052 hasConcept C136229726 @default.
• W1911378052 hasConcept C141071460 @default.
• W1911378052 hasConcept C183529106 @default.
• W1911378052 hasConcept C185592680 @default.
• W1911378052 hasConcept C197336794 @default.
• W1911378052 hasConcept C2776694085 @default.
• W1911378052 hasConcept C2777100477 @default.
• W1911378052 hasConcept C2777802072 @default.
• W1911378052 hasConcept C2778271429 @default.
• W1911378052 hasConcept C2780394083 @default.
• W1911378052 hasConcept C33923547 @default.
• W1911378052 hasConcept C41625074 @default.
• W1911378052 hasConcept C43617362 @default.
• W1911378052 hasConcept C502942594 @default.
• W1911378052 hasConcept C50670333 @default.
• W1911378052 hasConcept C55493867 @default.
• W1911378052 hasConcept C71924100 @default.
• W1911378052 hasConcept C98274493 @default.
• W1911378052 hasConceptScore W1911378052C118487528 @default.
• W1911378052 hasConceptScore W1911378052C126838900 @default.
• W1911378052 hasConceptScore W1911378052C134306372 @default.
• W1911378052 hasConceptScore W1911378052C136229726 @default.
• W1911378052 hasConceptScore W1911378052C141071460 @default.
• W1911378052 hasConceptScore W1911378052C183529106 @default.
• W1911378052 hasConceptScore W1911378052C185592680 @default.
• W1911378052 hasConceptScore W1911378052C197336794 @default.
• W1911378052 hasConceptScore W1911378052C2776694085 @default.
• W1911378052 hasConceptScore W1911378052C2777100477 @default.
• W1911378052 hasConceptScore W1911378052C2777802072 @default.
• W1911378052 hasConceptScore W1911378052C2778271429 @default.
• W1911378052 hasConceptScore W1911378052C2780394083 @default.
• W1911378052 hasConceptScore W1911378052C33923547 @default.
• W1911378052 hasConceptScore W1911378052C41625074 @default.
• W1911378052 hasConceptScore W1911378052C43617362 @default.
• W1911378052 hasConceptScore W1911378052C502942594 @default.
• W1911378052 hasConceptScore W1911378052C50670333 @default.
• W1911378052 hasConceptScore W1911378052C55493867 @default.
• W1911378052 hasConceptScore W1911378052C71924100 @default.
• W1911378052 hasConceptScore W1911378052C98274493 @default.

• next